Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Newly Added Patents
About This List
- This screen lists the current month's NEW ADDITIONS or NEW CHANGES to the patents for drugs listed in the Orange Book.
- This list will be purged after the Cumulative Supplement to the Orange Book is published on the first day of the next month. All the information listed on this screen is also available by using the other Orange Book search methods, such as searching by Proprietary Name.
- Patents will remain available in the Orange Book even when they are no longer listed as NEW additions or NEW changes.
Additional Information about Patents
- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.
Appl No | Active Ingredient | Proprietary Name | Dosage Form | Route | Strength | Patent No | Patent Expire Date | Drug Substance | Drug Product | Patent Use Code | Delist Requested | Mkt. Status | Submission Date |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Appl No | Active Ingredient | Proprietary Name | Dosage Form | Route | Strength | Patent No | Patent Expire Date | Drug Substance | Drug Product | Patent Use Code | Delist Requested | Mkt. Status | Submission Date |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 10183020 | 01/02/2035 | DP | U-3016 | RX | 02/12/2019 | ||
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 10183020 | 01/02/2035 | DP | U-3823 | RX | 02/12/2019 | ||
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 10183020 | 01/02/2035 | DP | U-1777 | RX | 02/12/2019 | ||
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 10183020 | 01/02/2035 | DP | U-2289 | RX | 02/12/2019 | ||
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 10183020 | 01/02/2035 | DP | U-3016 | RX | 02/12/2019 | ||
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 10183020 | 01/02/2035 | DP | U-3823 | RX | 02/12/2019 | ||
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 10183020 | 01/02/2035 | DP | U-1777 | RX | 02/12/2019 | ||
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 10183020 | 01/02/2035 | DP | U-2289 | RX | 02/12/2019 | ||
N209899 | OZANIMOD HYDROCHLORIDE | ZEPOSIA | CAPSULE | ORAL | EQ 0.23MG BASE | 10239846 | 11/15/2030 | U-3740 | RX | 06/22/2021 | |||
N209899 | OZANIMOD HYDROCHLORIDE | ZEPOSIA | CAPSULE | ORAL | EQ 0.92MG BASE | 10239846 | 11/15/2030 | U-3740 | RX | 06/22/2021 | |||
N209899 | OZANIMOD HYDROCHLORIDE | ZEPOSIA | CAPSULE | ORAL | EQ 0.46MG BASE | 10239846 | 11/15/2030 | U-3740 | RX | 06/22/2021 | |||
N207793 | IRINOTECAN HYDROCHLORIDE | ONIVYDE | INJECTABLE, LIPOSOMAL | INTRAVENOUS | EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) | 11344552 | 08/19/2036 | U-3824 | RX | 03/12/2024 | |||
N210656 | GLASDEGIB MALEATE | DAURISMO | TABLET | ORAL | EQ 25MG BASE | 11891372 | 04/13/2036 | U-3254 | RX | 03/06/2024 | |||
N210656 | GLASDEGIB MALEATE | DAURISMO | TABLET | ORAL | EQ 100MG BASE | 11891372 | 04/13/2036 | U-3254 | RX | 03/06/2024 | |||
N215320 | ACETAMINOPHEN; IBUPROFEN SODIUM | COMBOGESIC IV | SOLUTION | INTRAVENOUS | 1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML) | 11896567 | 10/26/2031 | U-3744 | RX | 03/12/2024 | |||
N215320 | ACETAMINOPHEN; IBUPROFEN SODIUM | COMBOGESIC IV | SOLUTION | INTRAVENOUS | 1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML) | 11896567 | 10/26/2031 | U-3745 | RX | 03/12/2024 | |||
N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 11896596 | 01/19/2043 | U-3715 | RX | 03/12/2024 | |||
N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 11896596 | 01/19/2043 | U-3720 | RX | 03/12/2024 | |||
N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 11896596 | 01/19/2043 | U-3719 | RX | 03/12/2024 | |||
N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 11896596 | 01/19/2043 | U-3718 | RX | 03/12/2024 | |||
N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 11896596 | 01/19/2043 | U-3717 | RX | 03/12/2024 | |||
N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 11896596 | 01/19/2043 | U-3716 | RX | 03/12/2024 | |||
N207921 | BECLOMETHASONE DIPROPIONATE | QVAR REDIHALER | AEROSOL, METERED | INHALATION | 0.08MG/INH | 11896759 | 01/26/2038 | DP | RX | 03/11/2024 | |||
N207921 | BECLOMETHASONE DIPROPIONATE | QVAR REDIHALER | AEROSOL, METERED | INHALATION | 0.04MG/INH | 11896759 | 01/26/2038 | DP | RX | 03/11/2024 | |||
N208944 | AMANTADINE HYDROCHLORIDE | GOCOVRI | CAPSULE, EXTENDED RELEASE | ORAL | EQ 137MG BASE | 11903908 | 12/04/2034 | U-3822 | RX | 03/08/2024 | |||
N208944 | AMANTADINE HYDROCHLORIDE | GOCOVRI | CAPSULE, EXTENDED RELEASE | ORAL | EQ 68.5MG BASE | 11903908 | 12/04/2034 | U-3822 | RX | 03/08/2024 | |||
N214133 | LEVOKETOCONAZOLE | RECORLEV | TABLET | ORAL | 150MG | 11903940 | 03/02/2040 | U-3821 | RX | 03/08/2024 | |||
N213978 | VARENICLINE TARTRATE | TYRVAYA | SPRAY | NASAL | EQ 0.03MG BASE/SPRAY | 11903941 | 10/19/2035 | U-1900 | RX | 03/08/2024 | |||
N213978 | VARENICLINE TARTRATE | TYRVAYA | SPRAY | NASAL | EQ 0.03MG BASE/SPRAY | 11903942 | 10/19/2035 | DP | RX | 03/08/2024 | |||
N213978 | VARENICLINE TARTRATE | TYRVAYA | SPRAY | NASAL | EQ 0.03MG BASE/SPRAY | 11903943 | 10/19/2035 | U-1900 | RX | 03/08/2024 | |||
N202293 | DAPAGLIFLOZIN | FARXIGA | TABLET | ORAL | 10MG | 11903955 | 03/09/2040 | U-3825 | RX | 03/13/2024 | |||
N214679 | TOPIRAMATE | EPRONTIA | SOLUTION | ORAL | 25MG/ML | 11911362 | 08/21/2040 | DP | U-3413 | RX | 03/12/2024 | ||
N214679 | TOPIRAMATE | EPRONTIA | SOLUTION | ORAL | 25MG/ML | 11911362 | 08/21/2040 | DP | U-3414 | RX | 03/12/2024 | ||
N214679 | TOPIRAMATE | EPRONTIA | SOLUTION | ORAL | 25MG/ML | 11911362 | 08/21/2040 | DP | U-3415 | RX | 03/12/2024 | ||
N213973 | RIPRETINIB | QINLOCK | TABLET | ORAL | 50MG | 11911370 | 12/30/2040 | DP | RX | 03/13/2024 | |||
N213978 | VARENICLINE TARTRATE | TYRVAYA | SPRAY | NASAL | EQ 0.03MG BASE/SPRAY | 11911380 | 10/19/2035 | U-1900 | RX | 03/08/2024 | |||
N213593 | OMEPRAZOLE; SODIUM BICARBONATE | KONVOMEP | FOR SUSPENSION | ORAL | 2MG/ML;84MG/ML | 11911473 | 07/16/2039 | U-624 | RX | 03/14/2024 | |||
N213593 | OMEPRAZOLE; SODIUM BICARBONATE | KONVOMEP | FOR SUSPENSION | ORAL | 2MG/ML;84MG/ML | 11911473 | 07/16/2039 | U-623 | RX | 03/14/2024 | |||
N022503 | METAXALONE | METAXALONE | TABLET | ORAL | 640MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 11918559 | 07/29/2039 | DP | DISCN | 03/13/2024 | |||
N213973 | RIPRETINIB | QINLOCK | TABLET | ORAL | 50MG | 11918564 | 12/30/2040 | DP | RX | 03/13/2024 | |||
N211340 | AMLODIPINE BENZOATE | KATERZIA | SUSPENSION | ORAL | EQ 1MG BASE/ML | 11918685 | 10/06/2037 | U-3447 | RX | 03/14/2024 | |||
N211340 | AMLODIPINE BENZOATE | KATERZIA | SUSPENSION | ORAL | EQ 1MG BASE/ML | 11918685 | 10/06/2037 | U-3448 | RX | 03/14/2024 | |||
N217677 | NIROGACESTAT HYDROBROMIDE | OGSIVEO | TABLET | ORAL | EQ 50MG BASE | 11925619 | 05/19/2043 | U-3754 | RX | 03/14/2024 | |||
N217677 | NIROGACESTAT HYDROBROMIDE | OGSIVEO | TABLET | ORAL | EQ 50MG BASE | 11925620 | 05/19/2043 | U-3754 | RX | 03/14/2024 | |||
N215430 | BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE | AUVELITY | TABLET, EXTENDED RELEASE | ORAL | 105MG;45MG | 11925636 | 01/20/2043 | U-3419 | RX | 03/14/2024 | |||
N022496 | BUPIVACAINE | EXPAREL | INJECTABLE, LIPOSOMAL | INJECTION | 133MG/10ML (13.3MG/ML) | 11925706 | 01/22/2041 | DP | U-3380 | RX | 03/15/2024 | ||
N022496 | BUPIVACAINE | EXPAREL | INJECTABLE, LIPOSOMAL | INJECTION | 266MG/20ML (13.3MG/ML) | 11925706 | 01/22/2041 | DP | U-3380 | RX | 03/15/2024 | ||
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 2MG | 6949571 | 05/23/2025 | DS | DP | U-106 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 2MG | 6949571 | 05/23/2025 | DS | DP | U-2088 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 2MG | 6949571 | 05/23/2025 | DS | DP | U-2428 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 2MG | 6949571 | 05/23/2025 | DS | DP | U-2089 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 2MG | 6949571 | 05/23/2025 | DS | DP | U-2429 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 4MG | 6949571 | 05/23/2025 | DS | DP | U-106 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 4MG | 6949571 | 05/23/2025 | DS | DP | U-2088 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 4MG | 6949571 | 05/23/2025 | DS | DP | U-2428 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 4MG | 6949571 | 05/23/2025 | DS | DP | U-2089 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 4MG | 6949571 | 05/23/2025 | DS | DP | U-2429 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 6MG | 6949571 | 05/23/2025 | DS | DP | U-106 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 6MG | 6949571 | 05/23/2025 | DS | DP | U-2088 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 6MG | 6949571 | 05/23/2025 | DS | DP | U-2428 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 6MG | 6949571 | 05/23/2025 | DS | DP | U-2089 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 6MG | 6949571 | 05/23/2025 | DS | DP | U-2429 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 8MG | 6949571 | 05/23/2025 | DS | DP | U-106 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 8MG | 6949571 | 05/23/2025 | DS | DP | U-2088 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 8MG | 6949571 | 05/23/2025 | DS | DP | U-2428 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 8MG | 6949571 | 05/23/2025 | DS | DP | U-2089 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 8MG | 6949571 | 05/23/2025 | DS | DP | U-2429 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 10MG | 6949571 | 05/23/2025 | DS | DP | U-106 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 10MG | 6949571 | 05/23/2025 | DS | DP | U-2088 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 10MG | 6949571 | 05/23/2025 | DS | DP | U-2428 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 10MG | 6949571 | 05/23/2025 | DS | DP | U-2089 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 10MG | 6949571 | 05/23/2025 | DS | DP | U-2429 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 12MG | 6949571 | 05/23/2025 | DS | DP | U-106 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 12MG | 6949571 | 05/23/2025 | DS | DP | U-2088 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 12MG | 6949571 | 05/23/2025 | DS | DP | U-2428 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 12MG | 6949571 | 05/23/2025 | DS | DP | U-2089 | RX | 11/19/2012 | |
N202834 | PERAMPANEL | FYCOMPA | TABLET | ORAL | 12MG | 6949571 | 05/23/2025 | DS | DP | U-2429 | RX | 11/19/2012 | |
N208277 | PERAMPANEL | FYCOMPA | SUSPENSION | ORAL | 0.5MG/ML | 6949571 | 05/23/2025 | DS | DP | U-106 | RX | 05/27/2016 | |
N208277 | PERAMPANEL | FYCOMPA | SUSPENSION | ORAL | 0.5MG/ML | 6949571 | 05/23/2025 | DS | DP | U-2088 | RX | 05/27/2016 | |
N208277 | PERAMPANEL | FYCOMPA | SUSPENSION | ORAL | 0.5MG/ML | 6949571 | 05/23/2025 | DS | DP | U-2428 | RX | 05/27/2016 | |
N208277 | PERAMPANEL | FYCOMPA | SUSPENSION | ORAL | 0.5MG/ML | 6949571 | 05/23/2025 | DS | DP | U-2089 | RX | 05/27/2016 | |
N208277 | PERAMPANEL | FYCOMPA | SUSPENSION | ORAL | 0.5MG/ML | 6949571 | 05/23/2025 | DS | DP | U-2429 | RX | 05/27/2016 | |
N202293 | DAPAGLIFLOZIN | FARXIGA | TABLET | ORAL | 5MG | 7456254 | 06/30/2025 | U-2139 | RX | 11/15/2017 | |||
N202293 | DAPAGLIFLOZIN | FARXIGA | TABLET | ORAL | 10MG | 7456254 | 06/30/2025 | U-2139 | RX | 11/15/2017 | |||
N021254 | FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | ADVAIR HFA | AEROSOL, METERED | INHALATION | 0.045MG/INH;EQ 0.021MG BASE/INH | 7500444 | 02/26/2026 | DP | Y | RX | |||
N021254 | FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | ADVAIR HFA | AEROSOL, METERED | INHALATION | 0.23MG/INH;EQ 0.021MG BASE/INH | 7500444 | 02/26/2026 | DP | Y | RX | |||
N021254 | FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | ADVAIR HFA | AEROSOL, METERED | INHALATION | 0.045MG/INH;EQ 0.021MG BASE/INH | 7500444*PED | 08/26/2026 | RX | |||||
N021254 | FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | ADVAIR HFA | AEROSOL, METERED | INHALATION | 0.23MG/INH;EQ 0.021MG BASE/INH | 7500444*PED | 08/26/2026 | RX | |||||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.2MG/INH | 8113199 | 10/23/2027 | DP | Y | RX | 08/28/2014 | ||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.05MG/INH | 8113199 | 10/23/2027 | DP | Y | RX | 06/13/2018 | ||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.2MG/INH | 8113199*PED | 04/23/2028 | RX | |||||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.05MG/INH | 8113199*PED | 04/23/2028 | RX | |||||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.2MG/INH | 8161968 | 02/05/2028 | DP | Y | RX | 08/28/2014 | ||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.05MG/INH | 8161968 | 02/05/2028 | DP | Y | RX | 06/13/2018 | ||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.2MG/INH | 8161968*PED | 08/05/2028 | RX | |||||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.05MG/INH | 8161968*PED | 08/05/2028 | RX | |||||
N202293 | DAPAGLIFLOZIN | FARXIGA | TABLET | ORAL | 5MG | 8431685 | 04/13/2025 | U-2139 | RX | 11/15/2017 | |||
N202293 | DAPAGLIFLOZIN | FARXIGA | TABLET | ORAL | 10MG | 8431685 | 04/13/2025 | U-2139 | RX | 11/15/2017 | |||
N202293 | DAPAGLIFLOZIN | FARXIGA | TABLET | ORAL | 5MG | 8461105 | 04/13/2025 | U-2139 | RX | 11/15/2017 | |||
N202293 | DAPAGLIFLOZIN | FARXIGA | TABLET | ORAL | 10MG | 8461105 | 04/13/2025 | U-2139 | RX | 11/15/2017 | |||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.2MG/INH | 8534281 | 03/08/2030 | DP | Y | RX | 08/28/2014 | ||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.05MG/INH | 8534281 | 03/08/2030 | DP | Y | RX | 06/13/2018 | ||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.2MG/INH | 8534281*PED | 09/08/2030 | RX | |||||
N205625 | FLUTICASONE FUROATE | ARNUITY ELLIPTA | POWDER | INHALATION | 0.05MG/INH | 8534281*PED | 09/08/2030 | RX | |||||
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 8946235 | 08/08/2032 | DS | DP | U-3016 | RX | 12/11/2015 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 8946235 | 08/08/2032 | DS | DP | U-3823 | RX | 12/11/2015 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 8946235 | 08/08/2032 | DS | DP | U-1777 | RX | 12/11/2015 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 8946235 | 08/08/2032 | DS | DP | U-2289 | RX | 12/11/2015 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 8946235 | 08/08/2032 | DS | DP | U-3016 | RX | 12/11/2015 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 8946235 | 08/08/2032 | DS | DP | U-3823 | RX | 12/11/2015 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 8946235 | 08/08/2032 | DS | DP | U-1777 | RX | 12/11/2015 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 8946235 | 08/08/2032 | DS | DP | U-2289 | RX | 12/11/2015 | |
N211349 | GILTERITINIB FUMARATE | XOSPATA | TABLET | ORAL | EQ 40MG BASE | 8969336 | 11/28/2032 | DS | DP | RX | 12/18/2018 | ||
N202293 | DAPAGLIFLOZIN | FARXIGA | TABLET | ORAL | 5MG | 9238076 | 04/15/2024 | U-2139 | RX | 11/15/2017 | |||
N202293 | DAPAGLIFLOZIN | FARXIGA | TABLET | ORAL | 10MG | 9238076 | 04/15/2024 | U-2139 | RX | 11/15/2017 | |||
N209195 | SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR | VOSEVI | TABLET | ORAL | 400MG;100MG;100MG | 9585906 | 03/21/2028 | DS | DP | U-2039 | Y | RX | 07/28/2017 |
N209195 | SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR | VOSEVI | TABLET | ORAL | 400MG;100MG;100MG | 9585906 | 03/21/2028 | DS | DP | U-2040 | Y | RX | 07/28/2017 |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 9732058 | 07/25/2032 | DS | DP | U-3016 | RX | 08/29/2017 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 9732058 | 07/25/2032 | DS | DP | U-3823 | RX | 08/29/2017 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 9732058 | 07/25/2032 | DS | DP | U-1777 | RX | 08/29/2017 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 40MG BASE | 9732058 | 07/25/2032 | DS | DP | U-2289 | RX | 08/29/2017 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 9732058 | 07/25/2032 | DS | DP | U-3016 | RX | 08/29/2017 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 9732058 | 07/25/2032 | DS | DP | U-3823 | RX | 08/29/2017 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 9732058 | 07/25/2032 | DS | DP | U-1777 | RX | 08/29/2017 | |
N208065 | OSIMERTINIB MESYLATE | TAGRISSO | TABLET | ORAL | EQ 80MG BASE | 9732058 | 07/25/2032 | DS | DP | U-2289 | RX | 08/29/2017 |
View a list of all patent use codes
View a list of all exclusivity codes
Last Updated March 18, 2024.